オハイオにおける地図状萎縮の臨床試験
オハイオ内の拠点で、地図状萎縮に関する7件の研究が参加者を募集しています。
オハイオ内の都市
公式研究テキスト（英語）
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
- Cincinnati Eye Institute, Cincinnati
- Cleveland Clinic Main Campus, Cleveland
被験者募集中第2/3相
60歳以上 · 全性別 · 2026/09/30更新 · NCT06635148A Phase 1/2 Study of the Safety and Efficacy of BRX011 Oral Administration Once Daily in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration
- Retina Associates of Cleveland - Beachwood, Beachwood
- Retina Associates of Cleveland, Cleveland
- Retina Associates of Cleveland - Middleburg Heights, Middleburg Heights
被験者募集中第1/2相
55歳以上 · 全性別 · 2026/09/23更新 · NCT07029945A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
- Cincinnati Eye Institute, Cincinnati
- University Hospitals Cleveland Medical Center, Cleveland
- The Ohio State University, Columbus
- 他1件
被験者募集中第3相
50歳〜85歳 · 全性別 · 2026/09/18更新 · NCT06541704A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251
- Cincinnati Eye Institute, Blue Ash
被験者募集中第2相
50歳以上 · 全性別 · 2026/09/15更新 · NCT05626114Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
- Cleveland Clinic Foundation-Cole Eye Institute, Cleveland
被験者募集中第2相
55歳以上 · 全性別 · 2026/09/10更新 · NCT06659445Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration
- Retina Associates of Cleveland, Beachwood
被験者募集中
60歳以上 · 全性別 · 2026/08/26更新 · NCT06662162Multicenter Clinical Study of the SING-IMT in Patients with Late-stage AMD
- Cleveland Clinic | Cole Eye Institute, Cleveland
被験者募集中
65歳以上 · 全性別 · 2024/12/03更新 · NCT05438732ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。